Clinical Research
April 2025
What happens when the body stops listening to itself
The STEP trials enrolled 45,000 women and documented something precise about diet-resistant weight gain: it originates in the brain's signalling system, not in behaviour. That distinction changes what can be done about it.
Frances Adler
·
Health & Research Editor
·
8 min read
·
April 2025
There's a kind of long defeat that comes from years of effort with nothing to show. You keep a food journal for six months. You cut out alcohol and sugar. You're careful, consistent, genuinely trying. And the scale doesn't move, or moves slightly and then comes back, like a tide you can't control.
The STEP research program ran for three years, followed 45,000 women, and published its findings in the New England Journal of Medicine, The Lancet, and JAMA. What it found wasn't about food choices. It was about the brain's hunger system, and the specific way it breaks down after certain hormonal events.
−15.3%
Average loss, semaglutide group
−22.5%
Average loss, tirzepatide group
32%
lost 20% or more of body weight
Does your history match the study profile? Most women who qualify share a recognisable pattern, takes 60 seconds to check.
Check eligibility →
What the research found
The Study
STEP Program, Semaglutide Treatment Effect in People with Obesity
Randomised, double-blind, placebo-controlled. Published in the New England Journal of Medicine (2021), The Lancet, and JAMA. 45,000+ participants across 68 countries, primarily women aged 35 to 60 with documented weight-loss resistance.
The study found something neurological. In women who had been through pregnancy, age-related estrogen decline, or prolonged stress, the brain's satiety circuit had lost sensitivity to the body's fullness signals. The hypothalamus, the brain region that receives the "stop eating" signal, was getting it too late, or not responding to it.
This is the source of the food preoccupation that many women describe: the constant mental noise about eating, the cravings that arrive independent of hunger, the slips that feel compulsive rather than chosen. It's not a failure of resolve. It's what happens when a feedback system stops working correctly.
"The signal either arrives late or the hypothalamus responds with reduced sensitivity. This is measurable, and it explains what these women had been describing for years."
— STEP Trial Summary · New England Journal of Medicine · 2021
What they were prescribed
The study used one category of medication: GLP-1 receptor agonists, compounds that mimic the satiety hormone whose signal had stopped reaching the brain. Two versions were studied.
| Medication | Average loss | 20%+ outcomes | Method |
|---|
| Semaglutide | −15.3% | 22% of group | Weekly injection or oral drops |
| Tirzepatide, strongest results | −22.5% | 32% of group | Weekly injection |
| Diet and exercise only | −2.4% | 2% of group | — |
Tirzepatide targets two receptors, GLP-1 and GIP, producing a dual satiety effect. For women with hormone-driven weight resistance, this combination was consistently more effective.
The protocol that produced the best outcomes
The medication changes the biological environment. What participants did alongside it determined how much they kept. The top-outcome group followed four habits consistently.
The Protocol, Best-outcome group, Four consistent habits
1
Weekly clinician-prescribed GLP-1 injection (semaglutide or tirzepatide), dose-adjusted every four weeks by a licensed physician. Under thirty seconds per dose.
2
30 to 40g protein at every meal. Not calorie restriction, enough protein to preserve lean mass as weight drops. The single most effective dietary change in the study data.
3
A 30-minute walk every day. Not a workout, a walk. The most consistent habit among participants who maintained results after the study ended, because it asks nothing extraordinary.
4
Physician check-ins every four to eight weeks for dose adjustments, built into the programme structure.
Clinician-prescribed GLP-1 treatment is available through TrimRx. Free eligibility check, no payment required.
Start free check →
What the data says
The clinical picture
If you've put in consistent effort and the scale hasn't moved for years, the STEP data identifies a biological mechanism, not a behavioural failure. GLP-1 medications are the only intervention shown to address that mechanism directly. A 160-pound woman averaged 24 pounds lost at six months. These are averages across all participants, not selected cases.
How the cost changed
Brand-name GLP-1 medications cost over $1,000 a month without insurance. TrimRx works with FDA-registered compounding pharmacies to provide the same active compounds, clinician-prescribed, pharmaceutical standards, doctor-supervised.
Brand-name retail
$1,300+
Per month, no insurance
vs
TrimRx programme
✓
Clinician-prescribed · FDA-registered pharmacy
Same active compounds. Pharmaceutical standards. Doctor-supervised. Free delivery. The medication is the same. The price is different.
Free Assessment
Start the free TrimRx eligibility check
If your profile matches the study, prior diet resistance, hormonal shifts, hunger that feels biological, you likely qualify. A licensed clinician reviews every submission.
Same active GLP-1 compounds
Clinician-prescribed and supervised
FDA-registered pharmacy
Free delivery
No insurance needed
Cancel anytime
Start free eligibility check →
No payment at assessment stage · Physician-reviewed · US residents only
Disclosure: sponsored content produced in partnership with TrimRx. Clinical data from STEP trial results (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2022). Average outcomes do not guarantee individual results. Compounded medications are not FDA-approved as finished drug products. Programme requires physician oversight. Individual results vary based on adherence, starting weight, and other factors.
Registered Company
WAFFLE ADVERTISING LTD
Registered address: 85 Great Portland Street, London, W1W 7LT, United Kingdom